Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
24
HKMPY Quote, Financials, Valuation and Earnings
Last price:
$42.73
Seasonality move
:
2.89%
Day range:
$42.35 - $42.73
52-week range:
$40.32 - $59.26
Dividend yield:
3.93%
P/E ratio:
12.75x
P/S ratio:
1.47x
P/B ratio:
2.11x
Volume:
2K
Avg. volume:
1.1K
1-year change:
-14.85%
Market cap:
$4.7B
Revenue:
$3.1B
EPS (TTM):
$3.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HKMPY
Hikma Pharmaceuticals Plc
|
-- | -- | -- | -- | -- |
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
$21.3M | -$0.23 | 84624.25% | -288.08% | $9.52 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | $7.99 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HKMPY
Hikma Pharmaceuticals Plc
|
$42.73 | -- | $4.7B | 12.75x | $0.72 | 3.93% | 1.47x |
|
APM
Aptorum Group Ltd.
|
$1.32 | -- | $9.4M | 8.94x | $0.00 | 0% | 6.32x |
|
AUTL
Autolus Therapeutics Plc
|
$1.55 | $9.52 | $412.5M | -- | $0.00 | 0% | 8.05x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$5.04 | $17.94 | $3.1M | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$4.17 | $104.00 | $17.4M | -- | $0.00 | 0% | -- |
|
TLSA
Tiziana Life Sciences Ltd.
|
$1.74 | $7.99 | $206.8M | -- | $0.00 | 0% | 2,803.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HKMPY
Hikma Pharmaceuticals Plc
|
37.21% | 0.789 | -- | 0.65x |
|
APM
Aptorum Group Ltd.
|
-- | -9.132 | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.892 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.246 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.585 | 0.95% | 4.03x |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | 0.602 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HKMPY
Hikma Pharmaceuticals Plc
|
-- | -- | 9.98% | 15.52% | -- | -- |
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | -- | -- |
Hikma Pharmaceuticals Plc vs. Competitors
-
Which has Higher Returns HKMPY or APM?
Aptorum Group Ltd. has a net margin of -- compared to Hikma Pharmaceuticals Plc's net margin of --. Hikma Pharmaceuticals Plc's return on equity of 15.52% beat Aptorum Group Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HKMPYHikma Pharmaceuticals Plc-- -- $4.1B APMAptorum Group Ltd.-- -- -- -
What do Analysts Say About HKMPY or APM?
Hikma Pharmaceuticals Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Aptorum Group Ltd. has an analysts' consensus of -- which suggests that it could grow by 11263.64%. Given that Aptorum Group Ltd. has higher upside potential than Hikma Pharmaceuticals Plc, analysts believe Aptorum Group Ltd. is more attractive than Hikma Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings HKMPYHikma Pharmaceuticals Plc0 0 0 APMAptorum Group Ltd.0 0 0 -
Is HKMPY or APM More Risky?
Hikma Pharmaceuticals Plc has a beta of 0.641, which suggesting that the stock is 35.889% less volatile than S&P 500. In comparison Aptorum Group Ltd. has a beta of -0.206, suggesting its less volatile than the S&P 500 by 120.612%.
-
Which is a Better Dividend Stock HKMPY or APM?
Hikma Pharmaceuticals Plc has a quarterly dividend of $0.72 per share corresponding to a yield of 3.93%. Aptorum Group Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hikma Pharmaceuticals Plc pays 48.09% of its earnings as a dividend. Aptorum Group Ltd. pays out -- of its earnings as a dividend. Hikma Pharmaceuticals Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HKMPY or APM?
Hikma Pharmaceuticals Plc quarterly revenues are --, which are smaller than Aptorum Group Ltd. quarterly revenues of --. Hikma Pharmaceuticals Plc's net income of -- is lower than Aptorum Group Ltd.'s net income of --. Notably, Hikma Pharmaceuticals Plc's price-to-earnings ratio is 12.75x while Aptorum Group Ltd.'s PE ratio is 8.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hikma Pharmaceuticals Plc is 1.47x versus 6.32x for Aptorum Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKMPYHikma Pharmaceuticals Plc1.47x 12.75x -- -- APMAptorum Group Ltd.6.32x 8.94x -- --
-
Which has Higher Returns HKMPY or AUTL?
Autolus Therapeutics Plc has a net margin of -- compared to Hikma Pharmaceuticals Plc's net margin of -373.3%. Hikma Pharmaceuticals Plc's return on equity of 15.52% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital HKMPYHikma Pharmaceuticals Plc-- -- $4.1B AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About HKMPY or AUTL?
Hikma Pharmaceuticals Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 514.34%. Given that Autolus Therapeutics Plc has higher upside potential than Hikma Pharmaceuticals Plc, analysts believe Autolus Therapeutics Plc is more attractive than Hikma Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings HKMPYHikma Pharmaceuticals Plc0 0 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is HKMPY or AUTL More Risky?
Hikma Pharmaceuticals Plc has a beta of 0.641, which suggesting that the stock is 35.889% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.
-
Which is a Better Dividend Stock HKMPY or AUTL?
Hikma Pharmaceuticals Plc has a quarterly dividend of $0.72 per share corresponding to a yield of 3.93%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hikma Pharmaceuticals Plc pays 48.09% of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend. Hikma Pharmaceuticals Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HKMPY or AUTL?
Hikma Pharmaceuticals Plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Hikma Pharmaceuticals Plc's net income of -- is lower than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Hikma Pharmaceuticals Plc's price-to-earnings ratio is 12.75x while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hikma Pharmaceuticals Plc is 1.47x versus 8.05x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKMPYHikma Pharmaceuticals Plc1.47x 12.75x -- -- AUTLAutolus Therapeutics Plc8.05x -- $21.1M -$78.6M
-
Which has Higher Returns HKMPY or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to Hikma Pharmaceuticals Plc's net margin of --. Hikma Pharmaceuticals Plc's return on equity of 15.52% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital HKMPYHikma Pharmaceuticals Plc-- -- $4.1B BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About HKMPY or BDRX?
Hikma Pharmaceuticals Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 3428.8%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Hikma Pharmaceuticals Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Hikma Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings HKMPYHikma Pharmaceuticals Plc0 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is HKMPY or BDRX More Risky?
Hikma Pharmaceuticals Plc has a beta of 0.641, which suggesting that the stock is 35.889% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.
-
Which is a Better Dividend Stock HKMPY or BDRX?
Hikma Pharmaceuticals Plc has a quarterly dividend of $0.72 per share corresponding to a yield of 3.93%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hikma Pharmaceuticals Plc pays 48.09% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. Hikma Pharmaceuticals Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HKMPY or BDRX?
Hikma Pharmaceuticals Plc quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals Plc quarterly revenues of --. Hikma Pharmaceuticals Plc's net income of -- is lower than Biodexa Pharmaceuticals Plc's net income of --. Notably, Hikma Pharmaceuticals Plc's price-to-earnings ratio is 12.75x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hikma Pharmaceuticals Plc is 1.47x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKMPYHikma Pharmaceuticals Plc1.47x 12.75x -- -- BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns HKMPY or NCNA?
NuCana Plc has a net margin of -- compared to Hikma Pharmaceuticals Plc's net margin of --. Hikma Pharmaceuticals Plc's return on equity of 15.52% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital HKMPYHikma Pharmaceuticals Plc-- -- $4.1B NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About HKMPY or NCNA?
Hikma Pharmaceuticals Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 498700.96%. Given that NuCana Plc has higher upside potential than Hikma Pharmaceuticals Plc, analysts believe NuCana Plc is more attractive than Hikma Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings HKMPYHikma Pharmaceuticals Plc0 0 0 NCNANuCana Plc0 1 0 -
Is HKMPY or NCNA More Risky?
Hikma Pharmaceuticals Plc has a beta of 0.641, which suggesting that the stock is 35.889% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.
-
Which is a Better Dividend Stock HKMPY or NCNA?
Hikma Pharmaceuticals Plc has a quarterly dividend of $0.72 per share corresponding to a yield of 3.93%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hikma Pharmaceuticals Plc pays 48.09% of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend. Hikma Pharmaceuticals Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HKMPY or NCNA?
Hikma Pharmaceuticals Plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Hikma Pharmaceuticals Plc's net income of -- is lower than NuCana Plc's net income of -$378.9K. Notably, Hikma Pharmaceuticals Plc's price-to-earnings ratio is 12.75x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hikma Pharmaceuticals Plc is 1.47x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKMPYHikma Pharmaceuticals Plc1.47x 12.75x -- -- NCNANuCana Plc-- -- -- -$378.9K
-
Which has Higher Returns HKMPY or TLSA?
Tiziana Life Sciences Ltd. has a net margin of -- compared to Hikma Pharmaceuticals Plc's net margin of --. Hikma Pharmaceuticals Plc's return on equity of 15.52% beat Tiziana Life Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HKMPYHikma Pharmaceuticals Plc-- -- $4.1B TLSATiziana Life Sciences Ltd.-- -- -- -
What do Analysts Say About HKMPY or TLSA?
Hikma Pharmaceuticals Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Tiziana Life Sciences Ltd. has an analysts' consensus of $7.99 which suggests that it could grow by 359.1%. Given that Tiziana Life Sciences Ltd. has higher upside potential than Hikma Pharmaceuticals Plc, analysts believe Tiziana Life Sciences Ltd. is more attractive than Hikma Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings HKMPYHikma Pharmaceuticals Plc0 0 0 TLSATiziana Life Sciences Ltd.1 0 0 -
Is HKMPY or TLSA More Risky?
Hikma Pharmaceuticals Plc has a beta of 0.641, which suggesting that the stock is 35.889% less volatile than S&P 500. In comparison Tiziana Life Sciences Ltd. has a beta of -0.047, suggesting its less volatile than the S&P 500 by 104.653%.
-
Which is a Better Dividend Stock HKMPY or TLSA?
Hikma Pharmaceuticals Plc has a quarterly dividend of $0.72 per share corresponding to a yield of 3.93%. Tiziana Life Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hikma Pharmaceuticals Plc pays 48.09% of its earnings as a dividend. Tiziana Life Sciences Ltd. pays out -- of its earnings as a dividend. Hikma Pharmaceuticals Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HKMPY or TLSA?
Hikma Pharmaceuticals Plc quarterly revenues are --, which are smaller than Tiziana Life Sciences Ltd. quarterly revenues of --. Hikma Pharmaceuticals Plc's net income of -- is lower than Tiziana Life Sciences Ltd.'s net income of --. Notably, Hikma Pharmaceuticals Plc's price-to-earnings ratio is 12.75x while Tiziana Life Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hikma Pharmaceuticals Plc is 1.47x versus 2,803.69x for Tiziana Life Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKMPYHikma Pharmaceuticals Plc1.47x 12.75x -- -- TLSATiziana Life Sciences Ltd.2,803.69x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
